Alessio Bruscaggin

4.8k total citations
24 papers, 587 citations indexed

About

Alessio Bruscaggin is a scholar working on Pathology and Forensic Medicine, Genetics and Cancer Research. According to data from OpenAlex, Alessio Bruscaggin has authored 24 papers receiving a total of 587 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pathology and Forensic Medicine, 13 papers in Genetics and 13 papers in Cancer Research. Recurrent topics in Alessio Bruscaggin's work include Lymphoma Diagnosis and Treatment (15 papers), Chronic Lymphocytic Leukemia Research (13 papers) and Cancer Genomics and Diagnostics (13 papers). Alessio Bruscaggin is often cited by papers focused on Lymphoma Diagnosis and Treatment (15 papers), Chronic Lymphocytic Leukemia Research (13 papers) and Cancer Genomics and Diagnostics (13 papers). Alessio Bruscaggin collaborates with scholars based in Italy, Switzerland and United States. Alessio Bruscaggin's co-authors include Davide Rossi, Valeria Spina, Gianluca Gaïdano, Silvia Rasi, Robin Foà, Sara Monti, Clara Deambrogi, Valter Gattei, Carmela Ciardullo and Raúl Rabadán and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Alessio Bruscaggin

24 papers receiving 583 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alessio Bruscaggin Italy 8 464 313 221 182 119 24 587
Christian Winther Eskelund Denmark 11 432 0.9× 274 0.9× 74 0.3× 343 1.9× 69 0.6× 29 561
Marco Fangazio Italy 10 483 1.0× 346 1.1× 75 0.3× 273 1.5× 220 1.8× 20 727
Marie Cornic France 13 301 0.6× 101 0.3× 210 1.0× 256 1.4× 87 0.7× 24 548
Chingiz Underbayev United States 10 335 0.7× 394 1.3× 166 0.8× 162 0.9× 230 1.9× 18 671
Carmela Ciardullo Italy 9 283 0.6× 356 1.1× 66 0.3× 125 0.7× 162 1.4× 19 476
Jerry Ping United States 9 249 0.5× 276 0.9× 58 0.3× 134 0.7× 65 0.5× 15 399
Elena Ruíz-Ballesteros Spain 8 299 0.6× 211 0.7× 64 0.3× 164 0.9× 96 0.8× 8 468
Maite Cazorla Spain 10 231 0.5× 138 0.4× 121 0.5× 324 1.8× 59 0.5× 12 558
Annette M. Staiger Germany 14 490 1.1× 224 0.7× 74 0.3× 409 2.2× 109 0.9× 27 714
Jeffrey Tang Canada 5 556 1.2× 233 0.7× 124 0.6× 353 1.9× 106 0.9× 8 714

Countries citing papers authored by Alessio Bruscaggin

Since Specialization
Citations

This map shows the geographic impact of Alessio Bruscaggin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alessio Bruscaggin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alessio Bruscaggin more than expected).

Fields of papers citing papers by Alessio Bruscaggin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alessio Bruscaggin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alessio Bruscaggin. The network helps show where Alessio Bruscaggin may publish in the future.

Co-authorship network of co-authors of Alessio Bruscaggin

This figure shows the co-authorship network connecting the top 25 collaborators of Alessio Bruscaggin. A scholar is included among the top collaborators of Alessio Bruscaggin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alessio Bruscaggin. Alessio Bruscaggin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Signori, Chiara, Martina Di Trani, Maria Cristina Pirosa, et al.. (2024). Early Assessment of Circulating Tumor (ct)DNA and Analysis of TP53 mutations in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma Treated with Glofitamab Monotherapy. Blood. 144(Supplement 1). 4356–4356. 1 indexed citations
2.
Bruscaggin, Alessio, et al.. (2024). Detection of Circulating Tumor DNA in Lymphoma Patients. Methods in molecular biology. 2865. 475–490. 1 indexed citations
3.
Trani, Martina Di, Francesco Corrado, Martina Sollini, et al.. (2023). Baseline circulating tumour DNA and interim PET predict response in relapsed/refractory classical Hodgkin lymphoma. British Journal of Haematology. 204(2). 514–524. 7 indexed citations
4.
Pirosa, Maria Cristina, Alessio Bruscaggin, Lodovico Terzi di Bergamo, et al.. (2023). Circulating tumor DNA of classical Hodgkin lymphoma.. Journal of Clinical Oncology. 41(16_suppl). 7516–7516. 1 indexed citations
5.
Stüssi, Georg, et al.. (2022). Genetics and epigenetics of CLL. Leukemia & lymphoma. 64(3). 551–563. 3 indexed citations
6.
Trani, Martina Di, Francesca Ricci, Martina Sollini, et al.. (2021). Circulating Tumor DNA Integrated with Interim [18F]FDG PET Is Highly Effective in Predicting Outcome of Relapsed/Refractory Classical Hodgkin Lymphoma Treated with the Begev Regimen. Blood. 138(Supplement 1). 3504–3504. 1 indexed citations
7.
Rossi, Davide, Valeria Spina, Alessio Bruscaggin, & Gianluca Gaïdano. (2019). Liquid biopsy in lymphoma. Haematologica. 104(4). 648–652. 46 indexed citations
8.
Moia, Riccardo, Chiara Favini, Valeria Spina, et al.. (2019). XPO1 Mutations May Identify Binet Α Chronic Lymphocytic Leukemia Patients with Shorter Time to First Treatment. Blood. 134(Supplement_1). 1743–1743. 3 indexed citations
9.
Rossi, Davide, Fary Diop, Elisa Spaccarotella, et al.. (2017). Diffuse large B-cell lymphoma genotyping on the liquid biopsy. Blood. 129(14). 1947–1957. 181 indexed citations
10.
Ferrero, Simone, Davide Rossi, Alessio Bruscaggin, et al.. (2017). KMT2D AND TP53 MUTATIONS PREDICT POOR PFS AND OS IN MANTLE CELL LYMPHOMA RECEIVING HIGH‐DOSE THERAPY AND ASCT: THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 PHASE III TRIAL. Hematological Oncology. 35(S2). 94–95. 2 indexed citations
11.
12.
Rossi, Davide, Alessio Bruscaggin, Sara Galimberti, et al.. (2015). The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study. Haematologica. 100(4). 517–524. 4 indexed citations
13.
14.
Rossi, Davide, Hossein Khiabanian, Valeria Spina, et al.. (2014). Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood. 123(14). 2139–2147. 228 indexed citations
15.
Rossi, Davide, Hossein Khiabanian, Carmela Ciardullo, et al.. (2013). Clinical Impact Of Small TP53 Mutated Subclones In Chronic Lymphocytic Leukemia. Blood. 122(21). 116–116. 8 indexed citations
16.
Rossi, Davide, Alessio Bruscaggin, Sara Monti, et al.. (2013). Molecular Lesions Of Signalling Pathway Genes In Indolent B-Cell Lymphoproliferations Mimicking Splenic Marginal Zone Lymphoma. Blood. 122(21). 4250–4250. 1 indexed citations
17.
Rossi, Davide, Silvia Rasi, Valeria Spina, et al.. (2012). The genome of chemorefractory chronic lymphocytic leukemia reveals frequent mutations of NOTCH1 and SF3B1. PubMed. 1(S2). S26–S28. 2 indexed citations
18.
Rasi, Silvia, Alessio Bruscaggin, Andrea Rinaldi, et al.. (2011). Saliva is a reliable and practical source of germline DNA for genome-wide studies in chronic lymphocytic leukemia. Leukemia Research. 35(10). 1419–1422. 6 indexed citations
19.
Fangazio, Marco, Silvia Rasi, Tiziana Vaisitti, et al.. (2011). Disruption of BIRC3 associates with Fludarabine Chemorefractoriness in TP53 Wild Type Chronic Lymphocytic Leukemia. Blood. 118(21). 466–466. 7 indexed citations
20.
Rasi, Silvia, Valeria Spina, Alessio Bruscaggin, et al.. (2010). A variant of theLRP4gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome. British Journal of Haematology. 152(3). 284–294. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christian Winther Eskelund Breakdown of academic impact, for papers by Marco Fangazio Breakdown of academic impact, for papers by Marie Cornic Breakdown of academic impact, for papers by Chingiz Underbayev Breakdown of academic impact, for papers by Carmela Ciardullo Breakdown of academic impact, for papers by Jerry Ping Breakdown of academic impact, for papers by Elena Ruíz-Ballesteros Breakdown of academic impact, for papers by Maite Cazorla Breakdown of academic impact, for papers by Annette M. Staiger Breakdown of academic impact, for papers by Jeffrey Tang
Rankless by CCL
2026